Central Serous Chorioretinopathy Treatments

A Mini Review

Pierluigi Iacono, Maurizio Battaglia Parodi, Bruno Falcomatà, Francesco Bandello

Research output: Contribution to journalArticle

Abstract

Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.

Original languageEnglish
Pages (from-to)76-83
Number of pages8
JournalOphthalmic Research
Volume55
Issue number2
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Central Serous Chorioretinopathy
Retinal Pigment Epithelium
Mineralocorticoid Receptor Antagonists
Therapeutics
Photochemotherapy
Vascular Endothelial Growth Factor A
Visual Acuity
Atrophy
Retina
Lasers
Observation
Recurrence

Keywords

  • Anti-vascular endothelial growth factor
  • Central serous chorioretinopathy
  • Laser treatment
  • Mineralocorticoid antagonists
  • Photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Central Serous Chorioretinopathy Treatments : A Mini Review. / Iacono, Pierluigi; Battaglia Parodi, Maurizio; Falcomatà, Bruno; Bandello, Francesco.

In: Ophthalmic Research, Vol. 55, No. 2, 01.01.2016, p. 76-83.

Research output: Contribution to journalArticle

@article{83d744ee07f94c19bcfddfe932055217,
title = "Central Serous Chorioretinopathy Treatments: A Mini Review",
abstract = "Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.",
keywords = "Anti-vascular endothelial growth factor, Central serous chorioretinopathy, Laser treatment, Mineralocorticoid antagonists, Photodynamic therapy",
author = "Pierluigi Iacono and {Battaglia Parodi}, Maurizio and Bruno Falcomat{\`a} and Francesco Bandello",
year = "2016",
month = "1",
day = "1",
doi = "10.1159/000441502",
language = "English",
volume = "55",
pages = "76--83",
journal = "Ophthalmic Research",
issn = "0030-3747",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Central Serous Chorioretinopathy Treatments

T2 - A Mini Review

AU - Iacono, Pierluigi

AU - Battaglia Parodi, Maurizio

AU - Falcomatà, Bruno

AU - Bandello, Francesco

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.

AB - Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.

KW - Anti-vascular endothelial growth factor

KW - Central serous chorioretinopathy

KW - Laser treatment

KW - Mineralocorticoid antagonists

KW - Photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=84954384994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954384994&partnerID=8YFLogxK

U2 - 10.1159/000441502

DO - 10.1159/000441502

M3 - Article

VL - 55

SP - 76

EP - 83

JO - Ophthalmic Research

JF - Ophthalmic Research

SN - 0030-3747

IS - 2

ER -